	US 12,281,307 B2
	Oligomers and oligomer conjugates
Hassan Javanbakht, Basel (CH); Søren Ottosen, Glostrup (DK); and Morten Lindow, Copenhagen (DK)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Feb. 27, 2023, as Appl. No. 18/114,626.
Application 18/114,626 is a division of application No. 17/013,374, filed on Sep. 4, 2020, granted, now 11,591,598.
Application 17/013,374 is a division of application No. 16/530,765, filed on Aug. 2, 2019, granted, now 10,767,181.
Application 16/530,765 is a continuation of application No. 14/714,004, filed on May 15, 2015, granted, now 10,421,967.
Claims priority of application No. 1408623 (GB), filed on May 15, 2014.
Prior Publication US 2024/0035032 A1, Feb. 1, 2024
Int. Cl. C12N 15/113 (2010.01); A61K 31/713 (2006.01); A61K 47/54 (2017.01); C12N 15/11 (2006.01); C12N 15/36 (2006.01); C12N 15/51 (2006.01)

CPC C12N 15/1131 (2013.01) [A61K 31/713 (2013.01); A61K 47/549 (2017.08); A61K 47/554 (2017.08); C12N 15/1133 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/346 (2013.01); C12N 2310/351 (2013.01); C12N 2310/3515 (2013.01); C12N 2320/30 (2013.01)]

1 Claim

1. An oligomer conjugate suitable for use in the treatment of a viral disorder, wherein said oligomer conjugate comprises:

a) at least one first oligomer region capable of modulating a target sequence of Hepatitis B Virus (HBV) to treat said viral disorder; and

b) a carrier component;

wherein said first oligomer region is 10-20 nucleotides in length;

wherein said carrier component is a asialoglycoprotein receptor (ASGP-R) targeting moiety or a cholesterol conjugate moiety; and

wherein said target sequence comprises at least part of a gene or a mRNA encoding HBx (SEQ ID NO: 1) or HBsAg (SEQ ID NO: 2) or a naturally-occurring variant thereof.